Document:

Exhibit
4.1

    

    THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED,
PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION
STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER
APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

    

    IN
ADDITION, THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT
BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF
ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT
IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A
PERIOD OF SIX (6) MONTHS IMMEDIATELY FOLLOWING THE DATE OF EFFECTIVENESS OF THE
PUBLIC OFFERING OF THE COMPANY’S SECURITIES PURSUANT TO REGISTRATION STATEMENT
NO.: 333-162350 AS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(G)(2).

    

    CHINA
YONGXIN PHARMACEUTICALS, INC.

    

    UNDERWRITER’S
WARRANT

    

    [__________]
shares of Common Stock

    

    [__________],
2010

    

    This
UNDERWRITER’S WARRANT (this “Warrant”) of China Yongxin
Pharmaceuticals, Inc., a corporation duly organized and validly existing under
the laws of the State of Nevada (the “Company”), is being issued
pursuant to that certain Underwriting Agreement, dated as of [__________], 2010 (the “Underwriting Agreement”), by
and among the Company and Rodman & Renshaw, LLC, as the representative of
the underwriters named therein (the “Representatives”) relating to
a firm commitment public offering (the “Offering”) of [__________] shares of common
stock, $0.001 par value per share, of the Company (the “Common Stock”) underwritten by
the Representative and the underwriters named in the Underwriting
Agreement.

    

    FOR VALUE RECEIVED, the
Company hereby grants to Rodman & Renshaw LLC and its permitted successors
and assigns (collectively, the “Holder”) the right to purchase
from the Company up to [__________] ([__________]) shares of Common
Stock (such shares underlying this Warrant, the “Warrant Shares”), at a per
share purchase price equal to $[__________] (the “Exercise Price”), subject to
the terms, conditions and adjustments set forth below in this
Warrant.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    1.           Date of Warrant
Exercise.  This Warrant shall become exercisable on the date
that is one (1) year from the Base Date (the “Exercise Date”).  As
used in this Warrant, the term “Base Date” shall mean [__________],
2011.  Except as otherwise provided for herein or as permitted by
applicable rules of the Financial Industry Regulatory Authority, Inc., (“FINRA”)
this Warrant shall not be sold, transferred, assigned, pledged or hypothecated
prior to the Exercise Date.  The Warrant Shares are subject to a
180-day lock-up pursuant to FINRA Rule 5110(g)(1).

    

    2.           Expiration of
Warrant.  This Warrant shall expire on the four (4) year
anniversary of the Base Date (the “Expiration
Date”).

    

    3.           Exercise of
Warrant.  This Warrant shall be exercisable pursuant to the
terms of this Section 3.

    

    3.1          Manner of
Exercise.

    

    (a)           This
Warrant may only be exercised by the Holder hereof on or after the Exercise Date
and on or prior to the Expiration Date, in accordance with the terms and
conditions hereof, in whole or in part (but not as to fractional shares) with
respect to any portion of this Warrant, during the Company’s normal business
hours on any day other than a Saturday or a Sunday or a day on which commercial
banking institutions in New York, New York are authorized by law to be closed (a
“Business Day”), by
surrender of this Warrant to the Company at its office maintained pursuant to
Section 10.2(a) hereof, accompanied by a written exercise notice in the form
attached as Exhibit
A to this Warrant (or a reasonable facsimile thereof) duly executed by
the Holder, together with the payment of the aggregate Exercise Price for the
number of Warrant Shares purchased upon exercise of this
Warrant.  Upon surrender of this Warrant, the Company shall cancel
this Warrant document and shall, in the event of partial exercise, replace it
with a new Warrant document in accordance with Section 3.3

    

    (b)           Except
as provided for in Section 3.1(c) below, each exercise of this Warrant must be
accompanied by payment in full of the aggregate Exercise Price in cash by check
or wire transfer in immediately available funds for the number of Warrant Shares
being purchased by the Holder upon such exercise.

    

    (c)           The
aggregate Exercise Price for the number of Warrant Shares being purchased may
also, in the sole discretion of the Holder, be paid in full or in part on a
“cashless basis” at the election of the Holder:

    

    (i)           in
the form of Common Stock owned by the Holder (based on the Fair Market Value (as
defined below) of such Common Stock on the date of exercise);

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    (ii)          in
the form of Warrant Shares withheld by the Company from the Warrant Shares
otherwise to be received upon exercise of this Warrant having an aggregate Fair
Market Value on the date of exercise equal to the aggregate Exercise Price of
the Warrant Shares being purchased by the Holder; or

    

    (iii)         by
a combination of the foregoing, provided that the combined value of all cash and
the Fair Market Value of any shares surrendered to the Company is at least equal
to the aggregate Exercise Price for the number of Warrant Shares being purchased
by the Holder.

     

    For
purposes of this Warrant, the term “Fair Market Value” means with
respect to a particular date, the average closing price of the Common Stock for
the five (5) trading days immediately preceding the applicable exercise herein
as officially reported by the principal securities exchange on which the Common
Stock is then listed or admitted to trading, or, if the Common Stock is not
listed or admitted to trading on any securities exchange as determined in good
faith by resolution of the Board of Directors of the Company, based on the best
information available to it.

    

    For
purposes of illustration of a cashless exercise of this Warrant under Section
3.1(c)(ii) (or for a portion thereof for which cashless exercise treatment is
requested as contemplated by Section 3.1(c)(iii) hereof), the calculation of
such exercise shall be as follows:

    

    X = Y
(A-B)/A

    

    where:

    

    
      	 	
              X
      =

            	
              the
      number of Warrant Shares to be issued to the Holder (rounded to the
      nearest whole share).

            

    

    

    
      	 
      	
              Y
      =

            	
              the
      number of Warrant Shares with respect to which this Warrant is being
      exercised.

            

    

    

    
      	 
      	
              A
      =

            	
              the
      Fair Market Value of the Common
Stock.

            

    

    

    
      	 
      	
              B
      =

            	
              the
      Exercise Price.

            

    

    

    (d)          For
purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended,
understood, and acknowledged that the Common Stock issuable upon exercise of
this Warrant in a cashless exercise transaction as described in Section 3.1(c)
above shall be deemed to have been acquired at the time this Warrant was
issued.  Moreover, it is intended, understood, and acknowledged that
the holding period for the Common Stock issuable upon exercise of this Warrant
in a cashless exercise transaction as described in Section 3.1(c) above shall be
deemed to have commenced on the date this Warrant was
issued.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    3.2          When Exercise
Effective.  Each exercise of this Warrant shall be deemed to
have been effected immediately prior to the close of business on the Business
Day on which this Warrant shall have been duly surrendered to the Company as
provided in Sections 3.1 and 12 hereof, and, at such time, the Holder in whose
name any certificate or certificates for Warrant Shares shall be issuable upon
exercise as provided in Section 3.3 hereof shall be deemed to have become the
holder or holders of record thereof of the number of Warrant Shares purchased
upon exercise of this Warrant.

     

    3.3           Delivery of Common Stock
Certificates and New Warrant.  As soon as reasonably
practicable after each exercise of this Warrant, in whole or in part, and in any
event within five (5) Business Days thereafter, the Company, at its expense
(including the payment by it of any applicable issue taxes), will cause to be
issued in the name of and delivered to the Holder hereof or, subject to Sections
9 and 10 hereof, as the Holder (upon payment by the Holder of any applicable
transfer taxes) may direct:

    

    (a)           a
certificate or certificates (with appropriate restrictive legends, as
applicable) for the number of duly authorized, validly issued, fully paid and
nonassessable Warrant Shares to which the Holder shall be entitled upon
exercise; and

    

    (b)           in
case exercise is in part only, a new Warrant document of like tenor, dated the
date hereof, for the remaining number of Warrant Shares issuable upon exercise
of this Warrant after giving effect to the partial exercise of this Warrant
(including the delivery of any Warrant Shares as payment of the Exercise Price
for such partial exercise of this Warrant).

    

    4.           Certain
Adjustments.  For so long as this Warrant is
outstanding:

    

    4.1           Mergers or
Consolidations.  If at any time after the date hereof there
shall be a capital reorganization (other than a combination or subdivision of
Common Stock otherwise provided for herein) resulting in a reclassification to
or change in the terms of securities issuable upon exercise of this Warrant (a
“Reorganization”), or a
merger or consolidation of the Company with another corporation, association,
partnership, organization, business, individual, government or political
subdivision thereof or a governmental agency (a “Person” or the “Persons”) (other than a merger
with another Person in which the Company is a continuing corporation and which
does not result in any reclassification or change in the terms of securities
issuable upon exercise of this Warrant or a merger effected exclusively for the
purpose of changing the domicile of the Company) (a “Merger”), then, as a part of
such Reorganization or Merger, lawful provision and adjustment shall be made so
that the Holder shall thereafter be entitled to receive, upon exercise of this
Warrant, the number of shares of stock or any other equity or debt securities or
property receivable upon such Reorganization or Merger by a holder of the number
of shares of Common Stock which might have been purchased upon exercise of this
Warrant immediately prior to such Reorganization or Merger.  In any
such case, appropriate adjustment shall be made in the application of the
provisions of this Warrant with respect to the rights and interests of the
Holder after the Reorganization or Merger to the end that the provisions of this
Warrant (including adjustment of the Exercise Price then in effect and the
number of Warrant Shares) shall be applicable after that event, as near as
reasonably may be, in relation to any shares of stock, securities, property or
other assets thereafter deliverable upon exercise of this
Warrant.  The provisions of this Section 4.1 shall similarly apply to
successive Reorganizations and/or Mergers.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    4.2           Splits and Subdivisions;
Dividends.  In the event the Company should at any time or from
time to time effectuate a split or subdivision of the outstanding shares of
Common Stock or pay a dividend in or make a distribution payable in additional
shares of Common Stock or Common Stock Equivalents without payment of any
consideration by such holder for the additional shares of Common Stock or Common
Stock Equivalents (including the additional shares of Common Stock issuable upon
conversion or exercise thereof), then, as of the applicable record date (or the
date of such distribution, split or subdivision if no record date is fixed), the
per share Exercise Price shall be appropriately decreased and the number of
Warrant Shares shall be appropriately increased in proportion to such increase
(or potential increase) of outstanding shares; provided, however, that no
adjustment shall be made in the event the split, subdivision, dividend or
distribution is not effectuated.

    

    4.3           Combination of
Shares.  If the number of shares of Common Stock outstanding at
any time after the date hereof is decreased by a combination of the outstanding
shares of Common Stock, the per share Exercise Price shall be appropriately
increased and the number of shares of Warrant Shares shall be appropriately
decreased in proportion to such decrease in outstanding shares.

    

    4.4           Adjustments for Other
Distributions.  In the event the Company shall declare a
distribution payable in securities of other Persons, evidences of indebtedness
issued by the Company or other Persons, assets (excluding cash dividends or
distributions to the holders of Common Stock paid out of current or retained
earnings and declared by the Company’s board of directors) or options or rights
not referred to in Sections 4.2 or 4.3 then, in each such case for the purpose
of this Section 4.4, upon exercise of this Warrant, the Holder shall be entitled
to a proportionate share of any such distribution as though the Holder was the
actual record holder of the number of Warrant Shares as of the record date fixed
for the determination of the holders of Common Stock of the Company entitled to
receive such distribution.

    

    5.           No
Impairment.  The Company will not, by amendment of its articles
of incorporation or by-laws or through any consolidation, merger,
reorganization, transfer of assets, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist
in the carrying out of all of the terms and in the taking of all actions
necessary or appropriate in order to protect the rights of the Holder against
impairment.

    

    6.           Chief Financial Officer’s
Report as to Adjustments.  With respect to each adjustment
pursuant to Section 4 of this Warrant, the Company, at its expense, will
promptly compute the adjustment or re-adjustment in accordance with the terms of
this Warrant and cause its Chief Financial Officer to certify the computation
(other than any computation of the fair value of property of the Company, as the
case may be) and prepare a report setting forth, in reasonable detail, the event
requiring the adjustment or re-adjustment and the amount of such adjustment or
re-adjustment, the method of calculation thereof and the facts upon which the
adjustment or re-adjustment is based, and the Exercise Price and the number of
Warrant Shares or other securities purchasable hereunder after giving effect to
such adjustment or re-adjustment,  which report shall be mailed by
first class mail, postage prepaid to the Holder.  The Company will
also keep copies of all reports at its office maintained pursuant to Section
10.2(a) hereof and will cause them to be available for inspection at the office
during normal business hours upon reasonable notice by the Holder or any
prospective purchaser of the Warrant designated by the Holder
thereof.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    7.           Reservation of
Shares.  The Company shall, solely for the purpose of effecting
the exercise of this Warrant, at all times during the term of this Warrant,
reserve and keep available out of its authorized shares of Common Stock, free
from all taxes, liens and charges with respect to the issue thereof and not
subject to preemptive rights or other similar rights of shareholders of the
Company, such number of its shares of Common Stock as shall from time to time be
sufficient to effect in full the exercise of this Warrant.  If at any
time the number of authorized but unissued shares of Common Stock shall not be
sufficient to effect in full the exercise of this Warrant, in addition to such
other remedies as shall be available to Holder, the Company will promptly take
such corporate action as may, in the opinion of its counsel, be necessary to
increase the number of authorized but unissued shares of Common Stock to such
number of shares as shall be sufficient for such purposes, including without
limitation, using its Reasonable Best Efforts (as defined in Section 14 hereof)
to obtain the requisite shareholder approval necessary to increase the number of
authorized shares of Common Stock.  The Company hereby represents and
warrants that all shares of Common Stock issuable upon exercise of this Warrant
shall be duly authorized and, when issued and paid for upon exercise, shall be
validly issued, fully paid and nonassessable.

    

    8.           Registration and
Listing.

    

    8.1           Definition of Registrable
Securities; Majority.  As used herein, the term “Registrable Securities” means
any shares of Common Stock issuable upon the exercise of this Warrant, until the
date (if any) on which such shares shall have been transferred or exchanged and
new certificates for them not bearing a legend restricting further transfer
shall have been delivered by the Company and subsequent disposition of them
shall not require registration or qualification of them under the Securities Act
or any similar state law then in force.  For purposes of this Warrant,
the term “Majority”, in
reference to the holders of Registrable Securities, shall mean in excess of
fifty percent (50%) of the then outstanding Warrant Shares (assuming the
exercise of the entire Warrant) that: (i) are not held by the Company, an
affiliate, officer, creditor, employee or agent thereof or any of their
respective affiliates, members of their family, Persons acting as nominees or in
conjunction therewith and (ii) have not be resold to the public pursuant to a
registration statement filed under the Securities Act.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    8.2           Incidental Registration
Rights.

    

    (a)           If
the Company, at any time on or after the Base Date, proposes to register any of
its securities under the Securities Act (other than in connection with a
registration on Form S-4 or S-8 or any successor forms) whether for its own
account or for the account of any holder or holders of its shares other than
Registrable Securities (any shares of such holder or holders (but not those of
the Company and not Registrable Securities) with respect to any registration are
referred to herein as, “Other
Shares”), the Company shall each such time give prompt (but not less than
thirty (30) days prior to the anticipated effectiveness thereof) written notice
to the holders of Registrable Securities of its intention to do
so.  Upon the written request of any such holder of Registrable
Securities made within ten (10) days after the receipt of any such notice (which
request shall specify the Registrable Securities intended to be disposed of by
such holder), except as set forth in Section 8.2(b), the Company will use its
Reasonable Best Efforts to effect the registration under the Securities Act of
all of the Registrable Securities which the Company has been so requested to
register by such holder, to the extent requisite to permit the disposition of
the Registrable Securities so to be registered, by inclusion of such Registrable
Securities in the registration statement which covers the securities which the
Company proposes to register; provided, however, that if,
at any time after giving written notice of its intention to register any
securities and prior to the effective date of the registration statement filed
in connection with such registration, the Company shall determine for any reason
in its sole discretion either to not register, to delay or to withdraw
registration of such securities, the Company may, at its election, give written
notice of such determination to such holder and, thereupon: (i) in the case of a
determination not to register, shall be relieved of its obligation to register
any Registrable Securities in connection with such registration (but not from
its obligation to pay the Registration Expenses in connection therewith), (ii)
in the case of a determination to delay registration, shall be permitted to
delay registering any Registrable Securities for the same period as the delay in
registering such other securities (including the Other Shares), and (iii) in the
case of a determination to withdraw registration, shall be permitted to withdraw
registration.  The Company will pay all Registration Expenses in
connection with each registration of Registrable Securities pursuant to this
Section 8.2.

     

     (b)           If
the Company at any time proposes to register any of its securities under the
Securities Act as contemplated by this Section 8.2 and such securities are to be
distributed by or through one or more underwriters, the Company will, if
requested by a holder of Registrable Securities, use its Reasonable Best Efforts
to arrange for such underwriters to include all the Registrable Securities to be
offered and sold by such holder among the securities to be distributed by such
underwriters, provided that if the managing underwriter of such underwritten
offering shall inform the Company by letter of its belief that inclusion in such
distribution of all or a specified number of such securities proposed to be
distributed by such underwriters would interfere with the successful marketing
of the securities being distributed by such underwriters (such letter to state
the basis of such belief and the approximate number of such Registrable
Securities, such Other Shares and shares held by the Company proposed so to be
registered which may be distributed without such effect), then the Company may,
upon written notice to such holder, the other holders of Registrable Securities,
and holders of such Other Shares, reduce pro rata in accordance with the number
of shares of Common Stock desired to be included in such registration (if and to
the extent stated by such managing underwriter to be necessary to eliminate such
effect) the number of such Registrable Securities and Other Shares the
registration of which shall have been requested by each holder thereof so that
the resulting aggregate number of such Registrable Securities and Other Shares
so included in such registration, together with the number of securities to be
included in such registration for the account of the Company, shall be equal to
the number of shares stated in such managing underwriter’s
letter.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    8.3           Registration
Procedures.  Whenever the holders of Registrable Securities
have properly requested that any Registrable Securities be registered pursuant
to the terms of this Warrant, the Company shall use its Reasonable Best Efforts
to effect the registration and the sale of such Registrable Securities in
accordance with the intended method of disposition thereof, and pursuant thereto
the Company shall as expeditiously as possible:

     

    (a)           prepare
and file with the SEC a registration statement with respect to such Registrable
Securities and use its Reasonable Best Efforts to cause such registration
statement to become effective;

     

    (b)           notify
such holders of the effectiveness of each registration statement filed hereunder
and prepare and file with the SEC such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be
necessary to (i) keep such registration statement effective and the prospectus
included therein usable for a period commencing on the date that such
registration statement is initially declared effective by the SEC and ending on
the date when all Registrable Securities covered by such registration statement
have been sold pursuant to the registration statement or cease to be Registrable
Securities, and (ii) comply with the provisions of the Securities Act with
respect to the disposition of all securities covered by such registration
statement during such period in accordance with the intended methods of
disposition by the sellers thereof set forth in such registration
statement;

    

    (c)           furnish
to such holders such number of copies of such registration statement, each
amendment and supplement thereto, the prospectus included in such registration
statement (including each preliminary prospectus) and such other documents as
such seller may reasonably request in order to facilitate the disposition of the
Registrable Securities owned by such holders;

    

    (d)           use
its Reasonable Best Efforts to register or qualify such Registrable Securities
under such other securities or blue sky laws of such jurisdictions as such
holders reasonably request and do any and all other acts and things which may be
reasonably necessary or advisable to enable such holders to consummate the
disposition in such jurisdictions of the Registrable Securities owned by such
holders; provided,
however, that the Company shall not be required to: (i) qualify generally
to do business in any jurisdiction where it would not otherwise be required to
qualify but for this subparagraph; (ii) subject itself to taxation in any such
jurisdiction; or (iii) consent to general service of process in any such
jurisdiction;

    

    (e)           notify
such holders, at any time when a prospectus relating thereto is required to be
delivered under the Securities Act, of the happening of any event as a result of
which the prospectus included in such registration statement contains an untrue
statement of a material fact or omits any material fact necessary to make the
statements therein, in light of the circumstances in which they are made, not
materially misleading, and, at the reasonable request of such holders, the
Company shall prepare a supplement or amendment to such prospectus so that, as
thereafter delivered to the purchasers of such Registrable Securities, such
prospectus shall not contain an untrue statement of a material fact or omit to
state any material fact necessary to make the statements therein, in light of
the circumstances in which they are made, not materially
misleading;

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

    (f)     
      provide a transfer agent and registrar for
all such Registrable Securities not later than the effective date of such
registration statement;

    

    (g)           make
available for inspection by any underwriter participating in any disposition
pursuant to such registration statement, and any attorney, accountant or other
agent retained by any such underwriter, all financial and other records,
pertinent corporate documents and properties of the Company, and cause the
Company’s officers, directors, managers, employees and independent accountants
to supply all information reasonably requested by any such underwriter,
attorney, accountant or agent in connection with such registration
statement;

     

    (h)          otherwise
use its Reasonable Best Efforts to comply with all applicable rules and
regulations of the SEC, and make available to its security holders, as soon as
reasonably practicable, an earnings statement of the Company, which earnings
statement shall satisfy the provisions of Section 11(a) of the Securities Act
and, at the option of the Company, Rule 158 thereunder;

    

    (i)           in
the event of the issuance of any stop order suspending the effectiveness of a
registration statement, or of any order suspending or preventing the use of any
related prospectus or suspending the qualification of any Registrable Securities
included in such registration statement for sale in any jurisdiction, the
Company shall use its Reasonable Best Efforts promptly to obtain the withdrawal
of such order;

    

    (j)           use
its Reasonable Best Efforts to cause any Registrable Securities covered by such
registration statement to be registered with or approved by such other
governmental agencies or authorities as may be necessary to enable the sellers
thereof to consummate the disposition of such Registrable Securities;
and

    

    (k)           if
the offering is underwritten, use its Reasonable Best Efforts to furnish on the
date that Registrable Securities are delivered to the underwriters for sale
pursuant to such registration, an opinion dated such date of counsel
representing the Company for the purposes of such registration, addressed to the
underwriters covering such issues as are reasonably required by such
underwriters.

    

    8.4           Listing.  The
Company shall secure the listing of the Common Stock underlying this Warrant
upon each national securities exchange or automated quotation system upon which
shares of Common Stock are then listed or quoted (subject to official notice of
issuance) and shall maintain such listing of shares of Common
Stock.  The Company shall at all times comply in all material respects
with the Company’s reporting, filing and other obligations under the by-laws or
rules of The Nasdaq Capital Market (or such other national securities exchange
or market on which the Common Stock may then be listed, as
applicable).

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    8.6           Expenses.  The
Company shall pay all Registration Expenses relating to the registration and
listing obligations set forth in this Section 8.  For purposes of this
Warrant, the term “Registration
Expenses” means: (a) all registration, filing and FINRA (as defined
below) fees, (b) all reasonable fees and expenses of complying with securities
or blue sky laws, (c) all word processing, duplicating and printing expenses,
(d) the fees and disbursements of counsel for the Company and of its independent
public accountants, including the expenses of any special audits or “cold
comfort” letters required by or incident to such performance and compliance, (e)
premiums and other costs of policies of insurance (if any) against liabilities
arising out of the public offering of the Registrable Securities being
registered if the Company desires such insurance, if any, and (f) fees and
disbursements of one counsel for the selling holders of Registrable Securities;
provided however, that,
in any case where Registration Expenses are not to be borne by the Company, such
expenses shall not include (and such expenses shall be borne by the Company):
(i) salaries of Company personnel or general overhead expenses of the Company,
(ii) auditing fees, (iii) premiums or other expenses relating to liability
insurance required by underwriters of the Company, or (iv) other expenses for
the preparation of financial statements or other data, to the extent that any of
the foregoing either is normally prepared by the Company in the ordinary course
of its business or would have been incurred by the Company had no public
offering taken place.  Registration Expenses shall not include any
underwriting discounts and commissions which may be incurred in the sale of any
Registrable Securities and transfer taxes of the selling holders of Registrable
Securities.

     

    8.7           Information Provided by
Holders.  Any holder of Registrable Securities included in any
registration shall furnish to the Company such information as the Company may
reasonably request in writing to enable the Company to comply with the
provisions hereof in connection with any registration referred to in this
Warrant.

     

    8.8           FINRA Cobradesk
Filings.  In the event that a registration statement covering
the Registrable Securities is filed, within one (1) Business Day of the filing
of such registration statement, the Company will prepare and file the selling
stockholder resale offering described in such registration statement for review
by the Financial Industry Regulatory Authority (“FINRA”) via the FINRA’s
CobraDesk filing system (“CobraDesk Filing”) for the
purpose of having the prospectus contained within such registration statement
treated as a “base prospectus” in connection with such resale
offering.  The Company will use its Reasonable Best Efforts to have
the CobraDesk Filing approved by FINRA within thirty (30) days of such filing
date.  The Company shall bear all expenses of the CobraDesk Filing,
including fees and expenses of counsel or other advisors to the
Holder.  In all circumstances, the Company shall pay for all FINRA
filing fees associated with the CobraDesk Filing.

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    8.9           Effectiveness
Period.  The Company shall use its Reasonable Best Efforts to
keep each registration statement contemplated hereunder continuously effective
under the Securities Act until the date which is the earlier date of when (i)
all Registrable Securities covered by such Registration Statement have been sold
or (ii) all Registrable Securities covered by such Registration Statement may be
sold immediately without registration under the Securities Act and without
volume restrictions pursuant to Rule 144 under the Securities Act, as determined
by the counsel to the Company pursuant to a written opinion letter to such
effect, addressed and reasonably acceptable to the Company’s transfer agent and
the affected holders of Registrable Securities.

    

    8.10           Net Cash
Settlement.  Notwithstanding anything herein to the contrary,
in no event will the Holder hereof be entitled to receive a net-cash settlement
as liquidated damages in lieu of physical settlement in shares of Common Stock,
regardless of whether the Common Stock underlying this Warrant is registered
pursuant to an effective registration statement; provided, however, that the
foregoing will not preclude the Holder from seeking other remedies at law or
equity for breaches by the Company of its registration obligations
hereunder.

    

    9.           Restrictions on
Transfer.

    

    9.1           Restrictive
Legends.  This Warrant and each Warrant issued upon transfer or
in substitution for this Warrant pursuant to Section 10 hereof, each certificate
for Common Stock issued upon the exercise of the Warrant and each certificate
issued upon the transfer of any such Common Stock shall be transferable only
upon satisfaction of the conditions specified in this Section 9.  Each
of the foregoing securities shall be stamped or otherwise imprinted with a
legend reflecting the restrictions on transfer set forth herein and any
restrictions required under the Securities Act or other applicable securities
laws.

     

    9.2          Notice of Proposed
Transfer.  Prior to any transfer of any securities which are
not registered under an effective registration statement under the Securities
Act (“Restricted
Securities”), which transfer may only occur if there is an exemption from
the registration provisions of the Securities Act and all other applicable
securities laws, the Holder will give written notice to the Company of the
Holder’s intention to effect a transfer (and shall describe the manner and
circumstances of the proposed transfer). The following provisions shall apply to
any proposed transfer of Restricted Securities:

    

    (i)           If
in the opinion of counsel for the Holder reasonably satisfactory to the Company
the proposed transfer may be effected without registration of the Restricted
Securities under the Securities Act (which opinion shall state in detail the
basis of the legal conclusions reached therein), the Holder shall thereupon be
entitled to transfer the Restricted Securities in accordance with the terms of
the notice delivered by the Holder to the Company.  Each certificate
representing the Restricted Securities issued upon or in connection with any
transfer shall bear the restrictive legends required by Section 9.1
hereof.

    

    (ii)          If
the opinion called for in (i) above is not delivered, the Holder shall not be
entitled to transfer the Restricted Securities until either: (x) receipt by the
Company of a further notice from such Holder pursuant to the foregoing
provisions of this Section 9.2 and fulfillment of the provisions of clause (i)
above, or (y) such Restricted Securities have been effectively registered under
the Securities Act.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    

    9.3          Certain Other Transfer
Restrictions.  Notwithstanding any other provision of this
Section 9: (i) prior to the Exercise Date, this Warrant or the Restricted
Securities thereunder may only be transferred or assigned to the persons
permitted under FINRA Rule 5110(g), and (ii) no opinion of counsel shall be
necessary for a transfer of Restricted Securities by the holder thereof to any
Person employed by or owning equity in the Holder, if the transferee agrees in
writing to be subject to the terms hereof to the same extent as if the
transferee were the original purchaser hereof and such transfer is permitted
under applicable securities laws.

    

    9.4          Termination of
Restrictions.  Except as set forth in Section 9.3 hereof, the
restrictions imposed by this Section 9 upon the transferability of Restricted
Securities shall cease and terminate as to any particular Restricted Securities:
(a) which shall have been effectively registered under the Securities Act, or
(b) when, in the opinions of both counsel for the holder thereof and counsel for
the Company, such restrictions are no longer required in order to insure
compliance with the Securities Act or Section 10 hereof.  Whenever
such restrictions shall cease and terminate as to any Restricted Securities, the
Holder thereof shall be entitled to receive from the Company, without expense
(other than applicable transfer taxes, if any), new securities of like tenor not
bearing the applicable legends required by Section 9.1 hereof.

    

    10.         Ownership, Transfer, Sale
and Substitution of Warrant.

    

    10.1         Ownership of
Warrant.  The Company may treat any Person in whose name this
Warrant is registered in the Warrant Register maintained pursuant to Section
10.2(b) hereof as the owner and holder thereof for all purposes, notwithstanding
any notice to the contrary, except that, if and when any Warrant is properly
assigned in blank, the Company may (but shall not be obligated to) treat the
bearer thereof as the owner of such Warrant for all purposes, notwithstanding
any notice to the contrary.  Subject to Sections 9 and 10 hereof, this
Warrant, if properly assigned, may be exercised by a new holder without a new
Warrant first having been issued.

     

    10.2         Office; Exchange of
Warrant.

    

    (a)           The
Company will maintain its principal office at the location identified in the
prospectus relating to the Offering or at such other offices as set forth in the
Company’s most current filing (as of the date notice is to be given) under the
Exchange Act or as the Company otherwise notifies the Holder.

    

    (b)           The
Company shall cause to be kept at its office maintained pursuant to Section
10.2(a) hereof a Warrant Register for the registration and transfer of the
Warrant.  The name and address of the holder of the Warrant, the
transfers thereof and the name and address of the transferee of the Warrant
shall be registered in such Warrant Register.  The Person in whose
name the Warrant shall be so registered shall be deemed and treated as the owner
and holder thereof for all purposes of this Warrant, and the Company shall not
be affected by any notice or knowledge to the contrary.

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

    (c)           Upon
the surrender of this Warrant, properly endorsed, for registration of transfer
or for exchange at the office of the Company maintained pursuant to Section
10.2(a) hereof, the Company at its expense will (subject to compliance with
Section 9 hereof, if applicable) execute and deliver to or upon the order of the
Holder thereof a new Warrant of like tenor, in the name of such holder or as
such holder (upon payment by such holder of any applicable transfer taxes) may
direct, calling in the aggregate on the face thereof for the number of shares of
Common Stock called for on the face of the Warrant so surrendered (after giving
effect to any previous adjustment(s) to the number of Warrant
Shares).

    

    10.3        Replacement of
Warrant.  Upon receipt of evidence reasonably satisfactory to
the Company of the loss, theft, destruction or mutilation of this Warrant and,
in the case of any such loss, theft or destruction of this Warrant, upon
delivery of indemnity reasonably satisfactory to the Company in form and amount
or, in the case of any mutilation, upon surrender of this Warrant for
cancellation at the office of the Company maintained pursuant to Section 10.2(a)
hereof, the Company, at its expense, will execute and deliver, in lieu thereof,
a new Warrant of like tenor and dated the date hereof.

    

    10.4        Opinions.  In
connection with the sale of the Warrant Shares by Holder, the Company agrees to
cooperate with the Holder, and at the Company’s expense, have its counsel
provide any legal opinions required to remove the restrictive legends from the
Warrant Shares in connection with a sale, transfer or legend removal request of
Holder.

    

    11.          No Rights or Liabilities as
Stockholder.  No Holder shall be entitled to vote or receive
dividends or be deemed the holder of any shares of Common Stock or any other
securities of the Company which may at any time be issuable on the exercise
hereof for any purpose, nor shall anything contained herein be construed to
confer upon the Holder, as such, any of the rights of a stockholder of the
Company or any right to vote for the election of directors or upon any matter
submitted to stockholders at any meeting thereof, or to give or withhold consent
to any corporate action (whether upon any recapitalization, issuance of stock,
reclassification of stock, change of par value, consolidation, merger,
conveyance, or otherwise) or to receive notice of meetings, or to receive
dividends or subscription rights or otherwise until the Warrant shall have been
exercised and the shares of Common Stock purchasable upon the exercise hereof
shall have become deliverable, as provided herein.  The Holder will
not be entitled to share in the assets of the Company in the event of a
liquidation, dissolution or the winding up of the Company.

     

    12.           Notices.  Any
notice or other communication in connection with this Warrant shall be given in
writing and directed to the parties hereto as follows: (a) if to the Holder, c/o
John Borer III, Senior Managing Director (jborer@rodm.com), or
(b) if to the Company, to the attention of its Chief Executive Officer at its
office maintained pursuant to Section 10.2(a) hereof; provided, that the exercise
of the Warrant shall also be effected in the manner provided in Section 3
hereof.  Notices shall be deemed properly delivered and received when
delivered to the notice party (i) if personally delivered, upon receipt or
refusal to accept delivery, (ii) if sent via facsimile, upon mechanical
confirmation of successful transmission thereof generated by the sending
telecopy machine, (iii) if sent by a commercial overnight courier for delivery
on the next Business Day, on the first Business Day after deposit with such
courier service, or (iv) if sent by registered or certified mail, five (5)
Business Days after deposit thereof in the U.S. mail.

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

     

    13.           Payment of
Taxes.  The Company will pay all documentary stamp taxes
attributable to the issuance of shares of Common Stock underlying this Warrant
upon exercise of this Warrant; provided, however, that the
Company shall not be required to pay any tax which may be payable in respect of
any transfer involved in the transfer or registration of this Warrant or any
certificate for shares of Common Stock underlying this Warrant in a name other
that of the Holder.  The Holder is responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or
receiving shares of Common Stock underlying this Warrant upon exercise
hereof.

    

    14.           Miscellaneous.  This
Warrant and any term hereof may be changed, waived, discharged or terminated
only by an instrument in writing signed by the party against which enforcement
of the change, waiver, discharge or termination is sought.  This
Warrant shall be construed and enforced in accordance with and governed by the
laws of the State of New York.  The section headings in this Warrant
are for purposes of convenience only and shall not constitute a part
hereof.  When used herein, the term “Reasonable Best Efforts”
means, with respect to the applicable obligation of the Company, reasonable best
efforts for similarly situated, publicly-traded companies.

    

    IN WITNESS WHEREOF, the
Company has caused this Underwriter’s Warrant to be duly executed as of the date
first above written.

    

    
      
        
          
            	 
      	
                    CHINA
      YONGXIN PHARMACEUTICALS, INC.

                  
	 
      	 
      	 
      
	 
      	
                    By:

                  	
                     
      

                  
	 
      	 
      	
                    Name:  

                  
	 
      	 
      	
                    Title:   

                  

          

        

      

    

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

    EXHIBIT
A

    FORM
OF EXERCISE NOTICE

    [To be
executed only upon exercise of Warrant]

    

    To CHINA
YONGXIN PHARMACEUTICALS, INC.:

    

    The
undersigned registered holder of the within Warrant hereby irrevocably exercises
the Warrant pursuant to Section 3.1 of the Warrant with respect to
________________________ Warrant Shares, at an exercise price per share of
$[__________], and
requests that the certificates for such Warrant Shares be issued, subject to
Sections 9 and 10, in the name of, and delivered to:

    
      
        
          
            
              
                	 
        
	
                         
       

                      
	
                         
    

                      
	
                           
      

                      
	
                         
    

                      

              

            

          

        

      

    

    

    The
undersigned is hereby making payment for the Warrant Shares in the following
manner: [check one]

    

    
      	
               
      

            	
              

                ·

              

            	
              by
      cash in accordance with Section 3.1(b) of the
  Warrant

            

    

    

    
      	
               
      

            	
              

                ·

              

            	
              via
      cashless exercise in accordance with Section 3.1(c) of the Warrant in the
      following manner:

            

    

    
      
        
          
            	
                     
    

                  
	
                     
    

                  
	
                     
    

                  
	 
      

          

        

      

    

    The
undersigned hereby represents and warrants that it is, and has been since its
acquisition of the Warrant, the record and beneficial owner of the
Warrant.

    

    
      
        
          
            	
                    Dated:

                  	 
      

          

        

      

    

     

    
      
        
          
            
              	 
      
	
                      Print
      or Type Name

                    
	 
      
	 
      

            

          

        

      

    

    
      	
               (Signature
      must conform in all respects to name of holder as specified on the face of
      Warrant)

            

    

    

    
      
        
          	 
      
	
                   (Street
      Address)

                

        

      

    

    

    
      
        
          
            
              	 
      	 
      	 
      
	
                      (City)

                    	
                      (State)

                    	
                      (Zip
      Code)

                    

            

          

        

      

    

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
B

    FORM
OF ASSIGNMENT

    [To be
executed only upon transfer of Warrant]

    

    For value
received, the undersigned registered holder of the within Warrant hereby sells,
assigns and transfers unto _____________________ [include name and addresses]
the rights represented by the Warrant to purchase __________ shares of Common
Stock of CHINA YONGXIN PHARMACEUTICALS, INC. to which the Warrant relates, and
appoints _____________________ Attorney to make such transfer on the books of
CHINA YONGXIN PHARMACEUTICALS, INC. maintained for the purpose, with full power
of substitution in the premises.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          	 
      	
                                  Dated:

                                	 
          	
                                   
      

                                
	 
      	 
      	
                                  (Signature
      must conform in all respects

                                
	 
      	 
      	
                                  to
      name of holder as specified on the

                                
	 
      	 
      	
                                  face
      of Warrant)

                                
	 
      	 
      	 
      
	 
      	 
      	
                                   
      

                                
	 
      	 
      	
                                  (Street
      Address)

                                
	 
      	 
      	 
      
	 
      	 
      	
                                   
      

                                
	 
      	 
      	
                                  (City)                       
      (State)                       
      (Zip Code)

                                
	 
      	 
      	 
      
	 
      	
                                  Signed
      in the presence of:

                                	 
      
	 
      	 
      	 
      
	 
      	 
      	
                                   
      

                                
	 
      	 
      	
                                  (Signature
      of Transferee)

                                
	 
      	 
      	 
      
	 
      	 
      	 
        
	 
      	 
      	
                                  (Street
      Address)

                                
	 
      	 
      	 
      
	 
      	 
      	
                                   
      

                                
	 
      	 
      	
                                  (City)                       
      (State)                       
      (Zip Code)

                                
	 	 	 
	 
      	
                                  Signed
      in the presence of:

                                	
                                   
      

                                

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
        16Exhibit
10.3

     

    CORPORATE COMMUNICATIONS
CONSULTING AGREEMENT

     

    SECTION
1.0 SERVICE TO BE PROVIDED BY MICHAEL SOUTHWORTH OR ASSIGNEE.

     

    By virtue
of this Engagement subject to both parties being in compliance with the Terms
and Conditions contained herein, Michael Southworth, an individual residing at
2638 North Chestnut Circle, Mesa, Arizona 85213 (the “Consultant”) shall
undertake to provide to China Yongxin Pharmaceuticals, Inc., a Delaware
corporation having an office at 927 Canada Court, City of Industry, California
91748 (the “Company”);

     

    CORPORATE
COMMUNICATION SERVICES

     

    Company
hereby authorizes, appoints and engages Consultant, and Consultant agrees to be
available to consult with Company’s officers and directors for a period of three
months on projects agreed to in writing by the parties. Company may request
Consultant to work on projects in the following areas (“Consulting
Services”):

     

    
      	
              1.1

            	
              Consultant
      will provide consulting direction in regards to introduction and
      contacting, correspondence,
      and communication with new and existing
  investors.

            

    

     

    
      	
              1.2

            	
              Consultant
      shall undertake to provide further ongoing Corporate Communication
      Services by arranging
      and executing group presentations, conference calls to qualified Exchange
      Members, Shareholders, Portfolio Managers, Institutional Fund Managers,
      Pension Fund Managers, etc.

            

    

     

    
      	
              1.3

            	
              Consultant
      shall undertake to provide consulting on materials, which highlight
      Company’s history, business,
      status, prospects, strategies, etc., for distribution to qualified Capital
      Market Participants (includes current Shareholder, Industry Sector
      Investors, Brokers and Analysts, and the appropriate Financial Media). The
      materials will be prepared from information provided by the
      Client.

            

    

     

    
      	
              1.4

            	
              Consultant
      shall undertake to assist and provide consulting with the goal of taking
      Company to larger stock
      exchange status when ready.

            

    

     

    FURTHER:

     

    All
Services Shall Be On A best Efforts Basis.

     

    Consultant agrees that he will at all
times, faithfully and to the best of his experience, ability and talents,
perform all the duties and responsibilities outlined herein, pursuant to the
terms of this Agreement. Consultant does not guarantee that his efforts will
have any impact on Company’s business or that any subsequent financial
improvement or investments will result from Consultants efforts. Company
understands and acknowledges that the success or failure of Consultant’s efforts
will be predicated on Company’s business operations and results.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    All
information materials to be publicly circulated by Consultant on behalf of
Company shall be put before management for prior approval.

     

    SECTION
2.0 FEES & DISBURSEMENTS

     

    In
consideration for service Michael Southworth and associates will provide,
Company agrees to make payable to Michael Southworth or assignee the following
fees and disbursements:

     

    2.1
Compensation for services shall be paid as follows;

     

    
      	
            	
              a. 

            	
              Michael
      Southworth or assignee shall be issued One Million (1,000,000) shares in
      China Yongxin
      Pharmaceuticals, Inc.

            

    

    
      	
            	
              b. 

            	
              Michael
      Southworth shall be paid Thirty Five Thousand Dollars ($35,000) in cash as
      an initial sign
      on bonus. This payment is due and payable once the contract is in effect
      (See “consideration
      trigger” below, which fee is
non-refundable.

            

    

     

    The
obligations of the Company to issue One Million (1,000,000) shares of the above
mentioned stock and to pay the full cash consideration, will accrue and arise
only in the event the Company is successful in raising $250,000 minimum in the
anticipated upcoming private placement (the “consideration Trigger”). In the
event the consideration trigger is not reached by the date which is three (3)
months from the date of this Agreement, then the Company may terminate this
Agreement in accordance with Section 4.0 with no obligations
whatsoever.

    

    2.2
OPTIONS

    

    No
options shall be given to Consultant.

    

    2.3
DISBURSEMENTS

    

    Consultant
shall pay for its own expenses.

    

    2.4
INTEREST

    

    None
whatsoever.

    

    2.5
CURRENCY

    

    All funds
are to be paid in US currency.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SECTION 3.0 OBLIGATIONS OF
COMPANY

    

    By virtue of this Engagement and
subject to both parties being in compliance with the Terms and Conditions
contained herein, Company shall undertake to provide Consultant:

    

    3.1
INFORMATION

    

    Upon commencement of the Engagement,
Company shall provide Consultant a list of Corporate Information. Said list is
to be provided, and is required, to Consultant to perform the duties as
described herein. Company acknowledges that not all information provided to
Consultant will be utilized; however inclusion of such information is essential
for Consultant to perform its duties per the Engagement.

    

    Consultant
acknowledges that some information received to be of a highly confidential
nature, and warrants that said confidentiality shall be maintained at Company’s
request, provided such requests does not hinder Consultant’s ability to perform
its duties and/or cause Consultant to be in contravention of any applicable
legislation or restrictions relating to disclosure of material
facts.

    

    SECTION
4.0 TERMINATIONS

    

    4.1           Company
shall retain the right to terminate the Engagement at any time upon appropriate
notice being given to Consultant. Appropriate notice shall be deemed to be 30
days prior to the intended termination date. Consultant shall retain the right
to terminate the Engagement at anytime in the event that he cannot provide
services in accordance with
Section 1 of this Engagement.

    

    4.2           Upon
termination of this Engagement by either party, subject to the Consideration
Trigger set forth in Section 2.0 above, Company shall remain responsible for any
and all outstanding fees or disbursements payable to Consultant under this
Agreement, as per effective date of termination.

    

    SECTION
5.0 CONFIDENTIALITY

    

    5.1           Consultant
acknowledges that any and all knowledge or information concerning Company and
its affairs obtained by Consultant, it’s principals, employees and/or
contractors in the course of his engagement hereunder will be deemed
“confidential”, Consultant will not impart any such knowledge to any whosoever
during or after the term of hereof.

    

    As used
herein, “confidential” knowledge or information means: (a) all information
regarding Company, which is not generally available to the public; and (b) all
information regarding Company, which was received by Consultant from a source
with confidentiality obligations to Company.

    

    Consultant
shall, upon the termination of his Engagement by Company for any reason
whatsoever, immediately surrender and turn over to Company all “confidential”
material including, but not limited to, books, forms, records, papers/writings
and all other property relating or belonging to Company.

    

    This
section shall survive termination of this Agreement.

    

    SECTION
6.0 INDEMNITIES

    

    6.1           Company
does hereby agree to indemnify Consultant against any and all claims brought
against Consultant by third parties, said claims arising as a result of this
Agreement. In addition, Company agrees that any claims it may assert against
Consultant will be limited to the strict performance of this Agreement. Any
claims that may arise will exclude monetary damages.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      SECTION
7.0 REPRESENTATIONS OF COMPANY, INC. AND CONSULTANT

    

    

    Consultant
hereby represents and warrants as follows:

    

    7.1 POWER
AND AUTHORITY

    

    Consultant has the power to execute and
deliver this Agreement, has taken all action required by law to authorize such
execution and delivery, and this Agreement is a valid and binding obligation of
Consultant in accordance with its terms.

    

    7.2
INSIDE INFORMATION, SECURITES LAWS VIOLATIONS

    

    Consultant in the course of the
performance of its duties, may become aware of information which may considered
“inside information” within the meaning of the Federal Securities Laws, Rules
and Regulations. Consultant acknowledges that the use of such information to
purchase or sell securities of Company, or its affiliates, or to transmit such
information to any other party with a view to buy, sell, or otherwise deal in
Company securities, is prohibited by law and would constitute a breach of this
Agreement.

    

    Company
hereby represents and warrants as follows:

    

    This Agreement has been duly
authorized, and executed by Company and is a binding obligation of Company,
enforceable in accordance with its terms, except as rights to indemnity
hereunder may be limited by applicable federal or state securities laws, except
in each case as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditor’s rights
generally.

    

    SECTION
8.0 ALTERATION OF THIS AGREEMENT

    

    8.1          Any
notice, request, demand, or other communication given pursuant to the terms of
this Agreement shall be deemed given upon delivery, and may only be delivered or
sent via hand delivery, facsimile, or by overnight courier, correctly addressed
to the addresses of the parties indicated below or at such other address as such
party shall in writing have advised the other party.

     

    Michael
Southworth

    2638 N.
Chestnut Circle

    Mesa,
Arizona 85213

    

    China
Yongxin Pharmaceuticals, Inc.

    927
Canada Court

    City of
Industry, California 91748

    

    SECTION
10.0 INDEPENDENT CONTRACTOR

    

    Both
Company and the Consultant agree that the Consultant will act as an independent
contractor in the performance of his duties under this Agreement. Nothing
contained in this Agreement shall be construed to imply that Consultant, or any
employee, agent or other authorized representative of Consultant, is a partner,
joint venture, agent, officer or employee of Company. Neither party hereto shall
have any authority to bind the other in any respect vis a vis any third party,
it being intended that each shall remain an independent contractor and
responsible only for its actions.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    SECTION
11.0 CHOICE OF LAW AND VENUE

    

    This Agreement and the rights of the
parties hereunder shall be governed by and construed in accordance with the laws
of the State of Utah including all matters of construction, validity,
performance, and enforcement and without giving effect to the principles of
conflict of laws, any action brought by any party hereto shall be brought within
the County of Salt Lake, State of Utah.

    

    SECTION
12.0 SEVERABILITY

    

    If any provision of this Agreement is
unenforceable, invalid, or violates applicable law, such provision, or
unenforceable portion of such provision, shall be deemed stricken and shall not
affect the enforceability of any other provisions of this
Agreement.

     

    SECTION
13.0 MODIFICATION

    

    No change, modification, addition, or
amendment to this Agreement shall be valid unless in writing and signed by all
parties hereto.

    

    SECTION
14.0 SIGNATURES

    

    Agreement may be executed in one or
more counterparts, each of which shall be deemed an original, but all of which
shall together constitute one and the same instrument. Signature upon this
document shall signify acceptance of the terms and conditions of the Engagement
contained herein.

    

    IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be duly executed as of this date,
July 2nd, 2009.

     

    
      
        
          
            	
                    “COMPANY”

                  	
                    “CONSULTANT”

                  
	
                    [sig1]

                  	 
      
	
                    China
      Yongxin Pharmaceuticals, Inc.,

                  	 
      
	 
      	 
      
	
                    a
      Delaware corporation

                  	 
      

          

        
  

    

    
      
        
          
            
              
                
                  	 
      	 
      	
                          

                        
	 
      	 
      	 
      	 
      
	
                          By:

                        	 
      	 
      	
                          Michael
      Southworth, an individual

                        
	 
      	 
      	 
      	 
      
	
                          Its:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]